Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET [doxorubicin liposomal] Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2 [human epidermal growth factor receptor 2]-Positive Breast Cancer

Trial Profile

Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET [doxorubicin liposomal] Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2 [human epidermal growth factor receptor 2]-Positive Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Trastuzumab
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Sponsors Cephalon France; Teva Pharmaceutical Industries
  • Most Recent Events

    • 11 Oct 2016 Primary endpoint (Pathological complete response (pCR) in breast, upon histologic examination) has not been met according to the results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
    • 08 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top